Tumor responsiveness to statins requires overexpression of the ARF6 pathway

0Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The mevalonate pathway results in the prenylation of small GTPases, which are pivotal for oncogenesis and cancer malignancies. However, inhibitors of this pathway, such as statins, have not necessarily produced favorable results in clinical trials. We recently identified properties of statin responders, together with the underlying molecular mechanisms and simple biomarkers to predict these responders.

Cite

CITATION STYLE

APA

Sabe, H., Hashimoto, A., Hashimoto, S., & Oikawa, T. (2016, July 3). Tumor responsiveness to statins requires overexpression of the ARF6 pathway. Molecular and Cellular Oncology. Taylor and Francis Ltd. https://doi.org/10.1080/23723556.2016.1185564

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free